TY - JOUR AU - Ogino, S. AU - Galon, J. AU - Fuchs, C. S. AU - Dranoff, G. PY - 2011 DA - 2011// TI - Cancer immunology—analysis of host and tumor factors for personalized medicine JO - Nat Rev Clin Oncol VL - 8 UR - https://doi.org/10.1038/nrclinonc.2011.122 DO - 10.1038/nrclinonc.2011.122 ID - Ogino2011 ER - TY - JOUR AU - Hamada, T. AU - Keum, N. AU - Nishihara, R. AU - Ogino, S. PY - 2017 DA - 2017// TI - Molecular pathological epidemiology: new developing frontiers of big data science to study etiologies and pathogenesis JO - J Gastroenterol VL - 52 UR - https://doi.org/10.1007/s00535-016-1272-3 DO - 10.1007/s00535-016-1272-3 ID - Hamada2017 ER - TY - JOUR AU - Ogino, S. AU - Chan, A. T. AU - Fuchs, C. S. AU - Giovannucci, E. PY - 2011 DA - 2011// TI - Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field JO - Gut VL - 60 UR - https://doi.org/10.1136/gut.2010.217182 DO - 10.1136/gut.2010.217182 ID - Ogino2011 ER - TY - STD TI - U.S. National Library of Medicine. What is precision medicine? https://ghr.nlm.nih.gov/primer/precisionmedicine/definition. Accessed 16 May 2019. UR - https://ghr.nlm.nih.gov/primer/precisionmedicine/definition ID - ref4 ER - TY - JOUR AU - Cherny, N. I. AU - Vries, E. G. AU - Emanuel, L. AU - Fallowfield, L. AU - Francis, P. A. AU - Gabizon, A. PY - 2014 DA - 2014// TI - Words matter: distinguishing “personalized medicine” and “biologically personalized therapeutics” JO - J Natl Cancer Inst UR - https://doi.org/10.1093/jnci/dju321 DO - 10.1093/jnci/dju321 ID - Cherny2014 ER - TY - JOUR AU - Shariat, S. F. AU - Gust, K. M. PY - 2017 DA - 2017// TI - Immune therapy meets precision medicine JO - Lancet Oncol VL - 18 UR - https://doi.org/10.1016/s1470-2045(17)30098-0 DO - 10.1016/s1470-2045(17)30098-0 ID - Shariat2017 ER - TY - JOUR AU - Porta, C. A. M. AU - Zapperi, S. PY - 2017 DA - 2017// TI - Complexity in cancer stem cells and tumor evolution: toward precision medicine JO - Semin Cancer Biol VL - 44 UR - https://doi.org/10.1016/j.semcancer.2017.02.007 DO - 10.1016/j.semcancer.2017.02.007 ID - Porta2017 ER - TY - JOUR AU - Burnet, F. M. PY - 1970 DA - 1970// TI - The concept of immunological surveillance JO - Prog Exp Tumor Res VL - 13 UR - https://doi.org/10.1159/000386035 DO - 10.1159/000386035 ID - Burnet1970 ER - TY - JOUR AU - Thomas, L. PY - 1982 DA - 1982// TI - On immunosurveillance in human cancer JO - Yale J Biol Med VL - 55 ID - Thomas1982 ER - TY - JOUR AU - Corthay, A. PY - 2014 DA - 2014// TI - Does the immune system naturally protect against cancer? JO - Front Immunol VL - 5 UR - https://doi.org/10.3389/fimmu.2014.00197 DO - 10.3389/fimmu.2014.00197 ID - Corthay2014 ER - TY - JOUR AU - Coley, W. B. PY - 1910 DA - 1910// TI - The treatment of inoperable sarcoma by bacterial toxins (the mixed toxins of the Streptococcus erysipelas and the Bacillus prodigiosus) JO - Proc R Soc Med VL - 3 ID - Coley1910 ER - TY - JOUR AU - Singh, A. K. AU - McGuirk, J. P. PY - 2016 DA - 2016// TI - Allogeneic stem cell transplantation: a historical and scientific overview JO - Cancer Res VL - 76 UR - https://doi.org/10.1158/0008-5472.can-16-1311 DO - 10.1158/0008-5472.can-16-1311 ID - Singh2016 ER - TY - JOUR AU - Mittal, S. AU - Marshall, N. A. AU - Barker, R. N. AU - Vickers, M. A. PY - 2008 DA - 2008// TI - Immunomodulation against leukemias and lymphomas: a realistic future treatment? JO - Crit Rev Oncol/Hematol VL - 65 UR - https://doi.org/10.1016/j.critrevonc.2007.05.004 DO - 10.1016/j.critrevonc.2007.05.004 ID - Mittal2008 ER - TY - JOUR AU - Hentschke, P. AU - Barkholt, L. AU - Uzunel, M. AU - Mattsson, J. AU - Wersall, P. AU - Pisa, P. PY - 2003 DA - 2003// TI - Low-intensity conditioning and hematopoietic stem cell transplantation in patients with renal and colon carcinoma JO - Bone Marrow Transplant VL - 31 UR - https://doi.org/10.1038/sj.bmt.1703811 DO - 10.1038/sj.bmt.1703811 ID - Hentschke2003 ER - TY - JOUR AU - Balkwill, F. R. AU - Capasso, M. AU - Hagemann, T. PY - 2012 DA - 2012// TI - The tumor microenvironment at a glance JO - J Cell Sci VL - 125 UR - https://doi.org/10.1242/jcs.116392 DO - 10.1242/jcs.116392 ID - Balkwill2012 ER - TY - JOUR AU - Belli, C. AU - Trapani, D. AU - Viale, G. AU - D’Amico, P. AU - Duso, B. A. AU - Della Vigna, P. PY - 2018 DA - 2018// TI - Targeting the microenvironment in solid tumors JO - Cancer Treat Rev VL - 65 UR - https://doi.org/10.1016/j.ctrv.2018.02.004 DO - 10.1016/j.ctrv.2018.02.004 ID - Belli2018 ER - TY - JOUR AU - Saifi, M. AU - Maran, A. AU - Raynaud, P. AU - Picot, M. C. AU - Quittet, P. AU - Cartron, G. PY - 2010 DA - 2010// TI - High ratio of interfollicular CD8/FOXP3-positive regulatory T cells is associated with a high FLIPI index and poor overall survival in follicular lymphoma JO - Exp Ther Med VL - 1 UR - https://doi.org/10.3892/etm.2010.146 DO - 10.3892/etm.2010.146 ID - Saifi2010 ER - TY - JOUR AU - Michiels, C. AU - Tellier, C. AU - Feron, O. PY - 2016 DA - 2016// TI - Cycling hypoxia: a key feature of the tumor microenvironment JO - Biochem Biophys Acta VL - 1866 UR - https://doi.org/10.1016/j.bbcan.2016.06.004 DO - 10.1016/j.bbcan.2016.06.004 ID - Michiels2016 ER - TY - JOUR AU - Zimna, A. AU - Kurpisz, M. PY - 2015 DA - 2015// TI - Hypoxia-inducible factor-1 in physiological and pathophysiological angiogenesis: applications and therapies JO - Biomed Res Int VL - 2015 UR - https://doi.org/10.1155/2015/549412 DO - 10.1155/2015/549412 ID - Zimna2015 ER - TY - JOUR AU - Axelrod, M. L. AU - Cook, R. S. AU - Johnson, D. B. AU - Balko, J. M. PY - 2019 DA - 2019// TI - Biological consequences of MHC-II expression by tumor cells in cancer JO - Clin Cancer Res VL - 25 UR - https://doi.org/10.1158/1078-0432.ccr-18-3200 DO - 10.1158/1078-0432.ccr-18-3200 ID - Axelrod2019 ER - TY - JOUR AU - Vahidian, F. AU - Duijf, P. H. G. AU - Safarzadeh, E. AU - Derakhshani, A. AU - Baghbanzadeh, A. AU - Baradaran, B. PY - 2019 DA - 2019// TI - Interactions between cancer stem cells, immune system and some environmental components: friends or foes? JO - Immunol Lett VL - 208 UR - https://doi.org/10.1016/j.imlet.2019.03.004 DO - 10.1016/j.imlet.2019.03.004 ID - Vahidian2019 ER - TY - JOUR AU - Srivastava, P. K. AU - Duan, F. PY - 2013 DA - 2013// TI - Harnessing the antigenic fingerprint of each individual cancer for immunotherapy of human cancer: genomics shows a new way and its challenges JO - Cancer Immunol Immunother VL - 62 UR - https://doi.org/10.1007/s00262-013-1422-x DO - 10.1007/s00262-013-1422-x ID - Srivastava2013 ER - TY - JOUR AU - Bobisse, S. AU - Foukas, P. G. AU - Coukos, G. AU - Harari, A. PY - 2016 DA - 2016// TI - Neoantigen-based cancer immunotherapy JO - Ann Transl Med VL - 4 UR - https://doi.org/10.21037/atm.2016.06.17 DO - 10.21037/atm.2016.06.17 ID - Bobisse2016 ER - TY - JOUR AU - Cai, W. AU - Zhou, D. AU - Wu, W. AU - Tan, W. L. AU - Wang, J. AU - Zhou, C. PY - 2018 DA - 2018// TI - MHC class II restricted neoantigen peptides predicted by clonal mutation analysis in lung adenocarcinoma patients: implications on prognostic immunological biomarker and vaccine design JO - BMC Genom VL - 19 UR - https://doi.org/10.1186/s12864-018-4958-5 DO - 10.1186/s12864-018-4958-5 ID - Cai2018 ER - TY - STD TI - Highlights of prescribing information. KEYTRUDA® (pembrolizumab) for injection, for intravenous use. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125514s014lbl.pdf. Accessed 16 May 2019. UR - https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125514s014lbl.pdf ID - ref25 ER - TY - JOUR AU - Yang, L. AU - Lin, P. C. PY - 2017 DA - 2017// TI - Mechanisms that drive inflammatory tumor microenvironment, tumor heterogeneity, and metastatic progression JO - Semin Cancer Biol VL - 47 UR - https://doi.org/10.1016/j.semcancer.2017.08.001 DO - 10.1016/j.semcancer.2017.08.001 ID - Yang2017 ER - TY - JOUR AU - Detassis, S. AU - Grasso, M. AU - Vescovo, V. AU - Denti, M. A. PY - 2017 DA - 2017// TI - microRNAs make the call in cancer personalized medicine JO - Front Cell Dev Biol VL - 5 UR - https://doi.org/10.3389/fcell.2017.00086 DO - 10.3389/fcell.2017.00086 ID - Detassis2017 ER - TY - JOUR AU - Blander, J. M. AU - Longman, R. S. AU - Iliev, I. D. AU - Sonnenberg, G. F. AU - Artis, D. PY - 2017 DA - 2017// TI - Regulation of inflammation by microbiota interactions with the host JO - Nat Immunol VL - 18 UR - https://doi.org/10.1038/ni.3780 DO - 10.1038/ni.3780 ID - Blander2017 ER - TY - JOUR AU - Destexhe, E. AU - Prinsen, M. K. AU - Scholl, I. AU - Kuper, C. F. AU - Garcon, N. AU - Veenstra, S. PY - 2013 DA - 2013// TI - Evaluation of C-reactive protein as an inflammatory biomarker in rabbits for vaccine nonclinical safety studies JO - J Pharmacol Toxicol Methods VL - 68 UR - https://doi.org/10.1016/j.vascn.2013.04.003 DO - 10.1016/j.vascn.2013.04.003 ID - Destexhe2013 ER - TY - JOUR AU - Palmer, C. S. AU - Hussain, T. AU - Duette, G. AU - Weller, T. J. AU - Ostrowski, M. AU - Sada-Ovalle, I. PY - 2016 DA - 2016// TI - Regulators of glucose metabolism in CD4(+) and CD8(+) T Cells JO - Int Rev Immunol VL - 35 UR - https://doi.org/10.3109/08830185.2015.1082178 DO - 10.3109/08830185.2015.1082178 ID - Palmer2016 ER - TY - JOUR AU - Catalan, E. AU - Charni, S. AU - Jaime, P. AU - Aguilo, J. I. AU - Enriquez, J. A. AU - Naval, J. PY - 2015 DA - 2015// TI - MHC-I modulation due to changes in tumor cell metabolism regulates tumor sensitivity to CTL and NK cells JO - Oncoimmunology VL - 4 UR - https://doi.org/10.4161/2162402x.2014.985924 DO - 10.4161/2162402x.2014.985924 ID - Catalan2015 ER - TY - JOUR AU - Pampena, M. B. AU - Cartar, H. C. AU - Cueto, G. R. AU - Levy, E. M. AU - Blanco, P. A. AU - Barrio, M. M. PY - 2018 DA - 2018// TI - Dissecting the immune stimulation promoted by CSF-470 vaccine plus adjuvants in cutaneous melanoma patients: long term antitumor immunity and short term release of acute inflammatory reactants JO - Front Immunol VL - 9 UR - https://doi.org/10.3389/fimmu.2018.02531 DO - 10.3389/fimmu.2018.02531 ID - Pampena2018 ER - TY - JOUR AU - Kawamura, J. AU - Sugiura, F. AU - Sukegawa, Y. AU - Yoshioka, Y. AU - Hida, J. I. AU - Hazama, S. PY - 2018 DA - 2018// TI - Multicenter, phase II clinical trial of peptide vaccination with oral chemotherapy following curative resection for stage III colorectal cancer JO - Oncol Lett VL - 15 UR - https://doi.org/10.3892/ol.2018.7905 DO - 10.3892/ol.2018.7905 ID - Kawamura2018 ER - TY - JOUR AU - Obara, W. AU - Hara, I. AU - Kato, Y. AU - Kato, R. AU - Inoue, K. AU - Sato, F. PY - 2018 DA - 2018// TI - Immunotherapy with cancer peptides in combination with intravesical bacillus Calmette–Guerin for patients with non-muscle invasive bladder cancer JO - Cancer Immunol Immunother VL - 67 UR - https://doi.org/10.1007/s00262-018-2197-x DO - 10.1007/s00262-018-2197-x ID - Obara2018 ER - TY - JOUR AU - Miyazawa, M. AU - Katsuda, M. AU - Maguchi, H. AU - Katanuma, A. AU - Ishii, H. AU - Ozaka, M. PY - 2017 DA - 2017// TI - Phase II clinical trial using novel peptide cocktail vaccine as a postoperative adjuvant treatment for surgically resected pancreatic cancer patients JO - Int J Cancer VL - 140 UR - https://doi.org/10.1002/ijc.30510 DO - 10.1002/ijc.30510 ID - Miyazawa2017 ER - TY - JOUR AU - Noguchi, M. AU - Moriya, F. AU - Koga, N. AU - Matsueda, S. AU - Sasada, T. AU - Yamada, A. PY - 2016 DA - 2016// TI - A randomized phase II clinical trial of personalized peptide vaccination with metronomic low-dose cyclophosphamide in patients with metastatic castration-resistant prostate cancer JO - Cancer Immunol Immunother VL - 65 UR - https://doi.org/10.1007/s00262-015-1781-6 DO - 10.1007/s00262-015-1781-6 ID - Noguchi2016 ER - TY - JOUR AU - Takahashi, R. AU - Toh, U. AU - Iwakuma, N. AU - Takenaka, M. AU - Otsuka, H. AU - Furukawa, M. PY - 2014 DA - 2014// TI - Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patients JO - Breast Cancer Res VL - 16 UR - https://doi.org/10.1186/bcr3685 DO - 10.1186/bcr3685 ID - Takahashi2014 ER - TY - JOUR AU - Aruga, A. AU - Takeshita, N. AU - Kotera, Y. AU - Okuyama, R. AU - Matsushita, N. AU - Ohta, T. PY - 2013 DA - 2013// TI - Long-term vaccination with multiple peptides derived from cancer-testis antigens can maintain a specific T-cell response and achieve disease stability in advanced biliary tract cancer JO - Clin Cancer Res VL - 19 UR - https://doi.org/10.1158/1078-0432.ccr-12-3592 DO - 10.1158/1078-0432.ccr-12-3592 ID - Aruga2013 ER - TY - JOUR AU - Yoshimoto, T. AU - Morishima, N. AU - Okumura, M. AU - Chiba, Y. AU - Xu, M. AU - Mizuguchi, J. PY - 2009 DA - 2009// TI - Interleukins and cancer immunotherapy JO - Immunotherapy VL - 1 UR - https://doi.org/10.2217/imt.09.46 DO - 10.2217/imt.09.46 ID - Yoshimoto2009 ER - TY - JOUR AU - Humphries, C. PY - 2013 DA - 2013// TI - Adoptive cell therapy: honing that killer instinct JO - Nature VL - 504 UR - https://doi.org/10.1038/504S13a DO - 10.1038/504S13a ID - Humphries2013 ER - TY - JOUR AU - Rosenberg, S. A. PY - 2011 DA - 2011// TI - Cell transfer immunotherapy for metastatic solid cancer—what clinicians need to know JO - Nat Rev Clin Oncol VL - 8 UR - https://doi.org/10.1038/nrclinonc.2011.116 DO - 10.1038/nrclinonc.2011.116 ID - Rosenberg2011 ER - TY - JOUR AU - Makkouk, A. AU - Weiner, G. J. PY - 2015 DA - 2015// TI - Cancer immunotherapy and breaking immune tolerance: new approaches to an old challenge JO - Cancer Res VL - 75 UR - https://doi.org/10.1158/0008-5472.can-14-2538 DO - 10.1158/0008-5472.can-14-2538 ID - Makkouk2015 ER - TY - JOUR AU - Gao, X. AU - Mi, Y. AU - Guo, N. AU - Xu, H. AU - Xu, L. AU - Gou, X. PY - 2017 DA - 2017// TI - Cytokine-induced killer cells as pharmacological tools for cancer immunotherapy JO - Front Immunol VL - 8 UR - https://doi.org/10.3389/fimmu.2017.00774 DO - 10.3389/fimmu.2017.00774 ID - Gao2017 ER - TY - JOUR AU - Stavrou, D. AU - Bilzer, T. AU - Anzil, A. P. AU - Hulten, M. AU - Kaldrymidou, E. PY - 1981 DA - 1981// TI - Reactivity of tumor-infiltrating, blood, spleen and lymph node lymphocytes against syngeneic glioma target cells JO - Anticancer Res VL - 1 ID - Stavrou1981 ER - TY - JOUR AU - Lloyd, K. O. PY - 1993 DA - 1993// TI - Tumor antigens known to be immunogenic in man JO - Ann N Y Acad Sci VL - 690 UR - https://doi.org/10.1111/j.1749-6632.1993.tb43995.x DO - 10.1111/j.1749-6632.1993.tb43995.x ID - Lloyd1993 ER - TY - JOUR AU - Finn, O. J. AU - Jerome, K. R. AU - Henderson, R. A. AU - Pecher, G. AU - Domenech, N. AU - Magarian-Blander, J. PY - 1995 DA - 1995// TI - MUC-1 epithelial tumor mucin-based immunity and cancer vaccines JO - Immunol Rev VL - 145 UR - https://doi.org/10.1111/j.1600-065X.1995.tb00077.x DO - 10.1111/j.1600-065X.1995.tb00077.x ID - Finn1995 ER - TY - JOUR AU - Salmaninejad, A. AU - Zamani, M. R. AU - Pourvahedi, M. AU - Golchehre, Z. AU - Hosseini Bereshneh, A. AU - Rezaei, N. PY - 2016 DA - 2016// TI - Cancer/testis antigens: expression, regulation, tumor invasion, and use in immunotherapy of cancers JO - Immunol Invest VL - 45 UR - https://doi.org/10.1080/08820139.2016.1197241 DO - 10.1080/08820139.2016.1197241 ID - Salmaninejad2016 ER - TY - JOUR AU - Trumpfheller, C. AU - Longhi, M. P. AU - Caskey, M. AU - Idoyaga, J. AU - Bozzacco, L. AU - Keler, T. PY - 2012 DA - 2012// TI - Dendritic cell-targeted protein vaccines: a novel approach to induce T-cell immunity JO - J Intern Med VL - 271 UR - https://doi.org/10.1111/j.1365-2796.2011.02496.x DO - 10.1111/j.1365-2796.2011.02496.x ID - Trumpfheller2012 ER - TY - JOUR AU - Heninger, E. AU - Krueger, T. E. AU - Lang, J. M. PY - 2015 DA - 2015// TI - Augmenting antitumor immune responses with epigenetic modifying agents JO - Front Immunol VL - 6 UR - https://doi.org/10.3389/fimmu.2015.00029 DO - 10.3389/fimmu.2015.00029 ID - Heninger2015 ER - TY - JOUR AU - Kortenhorst, M. S. AU - Wissing, M. D. AU - Rodriguez, R. AU - Kachhap, S. K. AU - Jans, J. J. AU - Groep, P. PY - 2013 DA - 2013// TI - Analysis of the genomic response of human prostate cancer cells to histone deacetylase inhibitors JO - Epigenetics VL - 8 UR - https://doi.org/10.4161/epi.25574 DO - 10.4161/epi.25574 ID - Kortenhorst2013 ER - TY - JOUR AU - Figueroa, J. A. AU - Reidy, A. AU - Mirandola, L. AU - Trotter, K. AU - Suvorava, N. AU - Figueroa, A. PY - 2015 DA - 2015// TI - Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy JO - Int Rev Immunol VL - 34 UR - https://doi.org/10.3109/08830185.2015.1018419 DO - 10.3109/08830185.2015.1018419 ID - Figueroa2015 ER - TY - JOUR AU - Mardiros, A. AU - Santos, C. AU - McDonald, T. AU - Brown, C. E. AU - Wang, X. AU - Budde, L. E. PY - 2013 DA - 2013// TI - T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia JO - Blood VL - 122 UR - https://doi.org/10.1182/blood-2012-12-474056 DO - 10.1182/blood-2012-12-474056 ID - Mardiros2013 ER - TY - JOUR AU - Zou, Y. AU - Xu, W. AU - Li, J. PY - 2018 DA - 2018// TI - Chimeric antigen receptor-modified T cell therapy in chronic lymphocytic leukemia JO - J Hematol Oncol VL - 11 UR - https://doi.org/10.1186/s13045-018-0676-3 DO - 10.1186/s13045-018-0676-3 ID - Zou2018 ER - TY - JOUR AU - Grupp, S. A. AU - Kalos, M. AU - Barrett, D. AU - Aplenc, R. AU - Porter, D. L. AU - Rheingold, S. R. PY - 2013 DA - 2013// TI - Chimeric antigen receptor-modified T cells for acute lymphoid leukemia JO - N Engl J Med VL - 368 UR - https://doi.org/10.1056/NEJMoa1215134 DO - 10.1056/NEJMoa1215134 ID - Grupp2013 ER - TY - JOUR AU - Park, J. H. AU - Riviere, I. AU - Gonen, M. AU - Wang, X. AU - Senechal, B. AU - Curran, K. J. PY - 2018 DA - 2018// TI - Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia JO - N Engl J Med VL - 378 UR - https://doi.org/10.1056/NEJMoa1709919 DO - 10.1056/NEJMoa1709919 ID - Park2018 ER - TY - JOUR AU - Morgan, R. A. AU - Yang, J. C. AU - Kitano, M. AU - Dudley, M. E. AU - Laurencot, C. M. AU - Rosenberg, S. A. PY - 2010 DA - 2010// TI - Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2 JO - Mol Ther VL - 18 UR - https://doi.org/10.1038/mt.2010.24 DO - 10.1038/mt.2010.24 ID - Morgan2010 ER - TY - JOUR AU - Hay, K. A. AU - Hanafi, L. A. AU - Li, D. AU - Gust, J. AU - Liles, W. C. AU - Wurfel, M. M. PY - 2017 DA - 2017// TI - Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy JO - Blood VL - 130 UR - https://doi.org/10.1182/blood-2017-06-793141 DO - 10.1182/blood-2017-06-793141 ID - Hay2017 ER - TY - JOUR AU - Frey, N. V. AU - Porter, D. L. PY - 2016 DA - 2016// TI - Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia JO - Hematol Am Soc Hematol Educ Progr VL - 2016 UR - https://doi.org/10.1182/asheducation-2016.1.567 DO - 10.1182/asheducation-2016.1.567 ID - Frey2016 ER - TY - STD TI - U.S. National Library of Medicine. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/results?term=CART-cells&Search=Search. Accessed 16 May 2019. UR - https://clinicaltrials.gov/ct2/results%3fterm%3dCART-cells%26Search%3dSearch ID - ref59 ER - TY - JOUR AU - Shah, N. N. AU - Maatman, T. AU - Hari, P. AU - Johnson, B. PY - 2019 DA - 2019// TI - Multi targeted CAR-T cell therapies for B-cell malignancies JO - Front Oncol VL - 9 UR - https://doi.org/10.3389/fonc.2019.00146 DO - 10.3389/fonc.2019.00146 ID - Shah2019 ER - TY - JOUR AU - Schutz, A. AU - Oertli, D. AU - Marti, W. R. AU - Noppen, C. AU - Padovan, E. AU - Spagnoli, G. C. PY - 2001 DA - 2001// TI - Immunogenicity of nonreplicating recombinant vaccinia expressing HLA-A201 targeted or complete MART-1/Melan-A antigen JO - Cancer Gene Ther VL - 8 UR - https://doi.org/10.1038/sj.cgt.7700351 DO - 10.1038/sj.cgt.7700351 ID - Schutz2001 ER - TY - JOUR AU - Lafont, V. AU - Sanchez, F. AU - Laprevotte, E. AU - Michaud, H. A. AU - Gros, L. AU - Eliaou, J. F. PY - 2014 DA - 2014// TI - Plasticity of gammadelta T cells: impact on the anti-tumor response JO - Front Immunol VL - 5 UR - https://doi.org/10.3389/fimmu.2014.00622 DO - 10.3389/fimmu.2014.00622 ID - Lafont2014 ER - TY - JOUR AU - He, Y. AU - Wu, K. AU - Hu, Y. AU - Sheng, L. AU - Tie, R. AU - Wang, B. PY - 2014 DA - 2014// TI - Gammadelta T cell and other immune cells crosstalk in cellular immunity JO - J Immunol Res VL - 2014 UR - https://doi.org/10.1155/2014/960252 DO - 10.1155/2014/960252 ID - He2014 ER - TY - JOUR AU - Gober, H. J. AU - Kistowska, M. AU - Angman, L. AU - Jeno, P. AU - Mori, L. AU - Libero, G. PY - 2003 DA - 2003// TI - Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells JO - J Exp Med VL - 197 UR - https://doi.org/10.1084/jem.20021500 DO - 10.1084/jem.20021500 ID - Gober2003 ER - TY - JOUR AU - Poggi, A. AU - Zocchi, M. R. PY - 2014 DA - 2014// TI - Gammadelta T lymphocytes as a first line of immune defense: old and new ways of antigen recognition and implications for cancer immunotherapy JO - Front Immunol VL - 5 UR - https://doi.org/10.3389/fimmu.2014.00575 DO - 10.3389/fimmu.2014.00575 ID - Poggi2014 ER - TY - JOUR AU - Dunne, M. R. AU - Mangan, B. A. AU - Madrigal-Estebas, L. AU - Doherty, D. G. PY - 2010 DA - 2010// TI - Preferential Th1 cytokine profile of phosphoantigen-stimulated human Vgamma9Vdelta2 T cells JO - Mediat Inflamm VL - 2010 UR - https://doi.org/10.1155/2010/704941 DO - 10.1155/2010/704941 ID - Dunne2010 ER - TY - JOUR AU - Lafont, V. AU - Liautard, J. AU - Liautard, J. P. AU - Favero, J. PY - 2001 DA - 2001// TI - Production of TNF-alpha by human V gamma 9V delta 2 T cells via engagement of Fc gamma RIIIA, the low affinity type 3 receptor for the Fc portion of IgG, expressed upon TCR activation by nonpeptidic antigen JO - J Immunol VL - 166 UR - https://doi.org/10.4049/jimmunol.166.12.7190 DO - 10.4049/jimmunol.166.12.7190 ID - Lafont2001 ER - TY - JOUR AU - Wesch, D. AU - Peters, C. AU - Siegers, G. M. PY - 2014 DA - 2014// TI - Human gamma delta T regulatory cells in cancer: fact or fiction? JO - Front Immunol VL - 5 UR - https://doi.org/10.3389/fimmu.2014.00598 DO - 10.3389/fimmu.2014.00598 ID - Wesch2014 ER - TY - JOUR AU - Burjanadze, M. AU - Condomines, M. AU - Reme, T. AU - Quittet, P. AU - Latry, P. AU - Lugagne, C. PY - 2007 DA - 2007// TI - In vitro expansion of gamma delta T cells with anti-myeloma cell activity by Phosphostim and IL-2 in patients with multiple myeloma JO - Br J Haematol VL - 139 UR - https://doi.org/10.1111/j.1365-2141.2007.06754.x DO - 10.1111/j.1365-2141.2007.06754.x ID - Burjanadze2007 ER - TY - JOUR AU - Kunzmann, V. AU - Smetak, M. AU - Kimmel, B. AU - Weigang-Koehler, K. AU - Goebeler, M. AU - Birkmann, J. PY - 2012 DA - 2012// TI - Tumor-promoting versus tumor-antagonizing roles of gammadelta T cells in cancer immunotherapy: results from a prospective phase I/II trial JO - J Immunother VL - 35 UR - https://doi.org/10.1097/cji.0b013e318245bb1e DO - 10.1097/cji.0b013e318245bb1e ID - Kunzmann2012 ER - TY - JOUR AU - Paul, S. AU - Lal, G. PY - 2016 DA - 2016// TI - Regulatory and effector functions of gamma-delta (gammadelta) T cells and their therapeutic potential in adoptive cellular therapy for cancer JO - Int J Cancer VL - 139 UR - https://doi.org/10.1002/ijc.30109 DO - 10.1002/ijc.30109 ID - Paul2016 ER - TY - JOUR AU - Hoeres, T. AU - Smetak, M. AU - Pretscher, D. AU - Wilhelm, M. PY - 2018 DA - 2018// TI - Improving the efficiency of Vgamma9Vdelta2 T-cell immunotherapy in cancer JO - Front Immunol VL - 9 UR - https://doi.org/10.3389/fimmu.2018.00800 DO - 10.3389/fimmu.2018.00800 ID - Hoeres2018 ER - TY - JOUR AU - Golay, J. AU - Semenzato, G. AU - Rambaldi, A. AU - Foa, R. AU - Gaidano, G. AU - Gamba, E. PY - 2013 DA - 2013// TI - Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics JO - mAbs VL - 5 UR - https://doi.org/10.4161/mabs.26008 DO - 10.4161/mabs.26008 ID - Golay2013 ER - TY - JOUR AU - Davis, T. A. AU - White, C. A. AU - Grillo-Lopez, A. J. AU - Velasquez, W. S. AU - Link, B. AU - Maloney, D. G. PY - 1999 DA - 1999// TI - Single-agent monoclonal antibody efficacy in bulky non-Hodgkin’s lymphoma: results of a phase II trial of rituximab JO - J Clin Oncol VL - 17 UR - https://doi.org/10.1200/jco.1999.17.6.1851 DO - 10.1200/jco.1999.17.6.1851 ID - Davis1999 ER - TY - JOUR AU - Braza, M. S. AU - Klein, B. AU - Fiol, G. AU - Rossi, J. F. PY - 2011 DA - 2011// TI - gammadelta T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody JO - Haematologica VL - 96 UR - https://doi.org/10.3324/haematol.2010.029520 DO - 10.3324/haematol.2010.029520 ID - Braza2011 ER - TY - JOUR AU - Deniger, D. C. AU - Moyes, J. S. AU - Cooper, L. J. PY - 2014 DA - 2014// TI - Clinical applications of gamma delta T cells with multivalent immunity JO - Front Immunol VL - 5 UR - https://doi.org/10.3389/fimmu.2014.00636 DO - 10.3389/fimmu.2014.00636 ID - Deniger2014 ER - TY - JOUR AU - Braza, M. S. AU - Klein, B. PY - 2013 DA - 2013// TI - Anti-tumour immunotherapy with Vgamma9Vdelta2 T lymphocytes: from the bench to the bedside JO - Br J Haematol VL - 160 UR - https://doi.org/10.1111/bjh.12090 DO - 10.1111/bjh.12090 ID - Braza2013 ER - TY - JOUR AU - Capsomidis, A. AU - Benthall, G. AU - Acker, H. H. AU - Fisher, J. AU - Kramer, A. M. AU - Abeln, Z. PY - 2018 DA - 2018// TI - Chimeric antigen receptor-engineered human gamma delta t cells: enhanced cytotoxicity with retention of cross presentation JO - Mol Ther VL - 26 UR - https://doi.org/10.1016/j.ymthe.2017.12.001 DO - 10.1016/j.ymthe.2017.12.001 ID - Capsomidis2018 ER - TY - JOUR AU - Cooper, M. A. AU - Fehniger, T. A. AU - Caligiuri, M. A. PY - 2001 DA - 2001// TI - The biology of human natural killer-cell subsets JO - Trends Immunol VL - 22 UR - https://doi.org/10.1016/S1471-4906(01)02060-9 DO - 10.1016/S1471-4906(01)02060-9 ID - Cooper2001 ER - TY - JOUR AU - Anfossi, N. AU - Andre, P. AU - Guia, S. AU - Falk, C. S. AU - Roetynck, S. AU - Stewart, C. A. PY - 2006 DA - 2006// TI - Human NK cell education by inhibitory receptors for MHC class I JO - Immunity VL - 25 UR - https://doi.org/10.1016/j.immuni.2006.06.013 DO - 10.1016/j.immuni.2006.06.013 ID - Anfossi2006 ER - TY - JOUR AU - Thomas, L. M. AU - Peterson, M. E. AU - Long, E. O. PY - 2013 DA - 2013// TI - Cutting edge: NK cell licensing modulates adhesion to target cells JO - J Immunol VL - 191 UR - https://doi.org/10.4049/jimmunol.1301159 DO - 10.4049/jimmunol.1301159 ID - Thomas2013 ER - TY - JOUR AU - Rolle, A. AU - Pollmann, J. AU - Cerwenka, A. PY - 2013 DA - 2013// TI - Memory of infections: an emerging role for natural killer cells JO - PLoS Pathog VL - 9 UR - https://doi.org/10.1371/journal.ppat.1003548 DO - 10.1371/journal.ppat.1003548 ID - Rolle2013 ER - TY - JOUR AU - Klingemann, H. AU - Boissel, L. AU - Toneguzzo, F. PY - 2016 DA - 2016// TI - Natural killer cells for immunotherapy—advantages of the NK-92 Cell line over blood NK cells JO - Front Immunol VL - 7 UR - https://doi.org/10.3389/fimmu.2016.00091 DO - 10.3389/fimmu.2016.00091 ID - Klingemann2016 ER - TY - JOUR AU - Cheng, M. AU - Chen, Y. AU - Xiao, W. AU - Sun, R. AU - Tian, Z. PY - 2013 DA - 2013// TI - NK cell-based immunotherapy for malignant diseases JO - Cell Mol Immunol VL - 10 UR - https://doi.org/10.1038/cmi.2013.10 DO - 10.1038/cmi.2013.10 ID - Cheng2013 ER - TY - JOUR AU - Ochoa, A. C. AU - Gromo, G. AU - Alter, B. J. AU - Sondel, P. M. AU - Bach, F. H. PY - 1987 DA - 1987// TI - Long-term growth of lymphokine-activated killer (LAK) cells: role of anti-CD3, beta-IL 1, interferon-gamma and -beta JO - J Immunol VL - 138 ID - Ochoa1987 ER - TY - JOUR AU - Jiang, J. AU - Wu, C. AU - Lu, B. PY - 2013 DA - 2013// TI - Cytokine-induced killer cells promote antitumor immunity JO - J Transl Med VL - 11 UR - https://doi.org/10.1186/1479-5876-11-83 DO - 10.1186/1479-5876-11-83 ID - Jiang2013 ER - TY - JOUR AU - Schmidt-Wolf, I. G. AU - Negrin, R. S. AU - Kiem, H. P. AU - Blume, K. G. AU - Weissman, I. L. PY - 1991 DA - 1991// TI - Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity JO - J Exp Med VL - 174 UR - https://doi.org/10.1084/jem.174.1.139 DO - 10.1084/jem.174.1.139 ID - Schmidt-Wolf1991 ER - TY - JOUR AU - Muller, S. AU - Schulz, A. AU - Reiss, U. AU - Schwarz, K. AU - Schreiner, T. AU - Wiesneth, M. PY - 1999 DA - 1999// TI - Definition of a critical T cell threshold for prevention of GVHD after HLA non-identical PBPC transplantation in children JO - Bone Marrow Transplant VL - 24 UR - https://doi.org/10.1038/sj.bmt.1701970 DO - 10.1038/sj.bmt.1701970 ID - Muller1999 ER - TY - JOUR AU - Rubnitz, J. E. AU - Inaba, H. AU - Ribeiro, R. C. AU - Pounds, S. AU - Rooney, B. AU - Bell, T. PY - 2010 DA - 2010// TI - NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia JO - J Clin Oncol VL - 28 UR - https://doi.org/10.1200/jco.2009.24.4590 DO - 10.1200/jco.2009.24.4590 ID - Rubnitz2010 ER - TY - JOUR AU - Ali, J. AU - Harper, I. AU - Bolton, E. AU - Bradley, J. A. AU - Pettigrew, G. PY - 2015 DA - 2015// TI - Recipient natural killer cell allorecognition of passenger donor lymphocytes and its effect on adaptive alloimmunity after transplantation JO - Lancet VL - 385 UR - https://doi.org/10.1016/s0140-6736(15)60333-6 DO - 10.1016/s0140-6736(15)60333-6 ID - Ali2015 ER - TY - JOUR AU - Koehl, U. AU - Kalberer, C. AU - Spanholtz, J. AU - Lee, D. A. AU - Miller, J. S. AU - Cooley, S. PY - 2016 DA - 2016// TI - Advances in clinical NK cell studies: donor selection, manufacturing and quality control JO - Oncoimmunology VL - 5 UR - https://doi.org/10.1080/2162402x.2015.1115178 DO - 10.1080/2162402x.2015.1115178 ID - Koehl2016 ER - TY - JOUR AU - Lowry, L. E. AU - Zehring, W. A. PY - 2017 DA - 2017// TI - Potentiation of natural killer cells for cancer immunotherapy: a review of literature JO - Front Immunol VL - 8 UR - https://doi.org/10.3389/fimmu.2017.01061 DO - 10.3389/fimmu.2017.01061 ID - Lowry2017 ER - TY - JOUR AU - Korde, N. AU - Carlsten, M. AU - Lee, M. J. AU - Minter, A. AU - Tan, E. AU - Kwok, M. PY - 2014 DA - 2014// TI - A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma JO - Haematologica VL - 99 UR - https://doi.org/10.3324/haematol.2013.103085 DO - 10.3324/haematol.2013.103085 ID - Korde2014 ER - TY - JOUR AU - Verneris, M. R. AU - Miller, J. S. PY - 2009 DA - 2009// TI - The phenotypic and functional characteristics of umbilical cord blood and peripheral blood natural killer cells JO - Br J Haematol VL - 147 UR - https://doi.org/10.1111/j.1365-2141.2009.07768.x DO - 10.1111/j.1365-2141.2009.07768.x ID - Verneris2009 ER - TY - JOUR AU - Jiang, H. AU - Zhang, W. AU - Shang, P. AU - Zhang, H. AU - Fu, W. AU - Ye, F. PY - 2014 DA - 2014// TI - Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells JO - Mol Oncol VL - 8 UR - https://doi.org/10.1016/j.molonc.2013.12.001 DO - 10.1016/j.molonc.2013.12.001 ID - Jiang2014 ER - TY - JOUR AU - Mehta, R. S. AU - Rezvani, K. PY - 2018 DA - 2018// TI - Chimeric antigen receptor expressing natural killer cells for the immunotherapy of cancer JO - Front Immunol VL - 9 UR - https://doi.org/10.3389/fimmu.2018.00283 DO - 10.3389/fimmu.2018.00283 ID - Mehta2018 ER - TY - JOUR AU - Carreno, L. J. AU - Kharkwal, S. S. AU - Porcelli, S. A. PY - 2014 DA - 2014// TI - Optimizing NKT cell ligands as vaccine adjuvants JO - Immunotherapy VL - 6 UR - https://doi.org/10.2217/imt.13.175 DO - 10.2217/imt.13.175 ID - Carreno2014 ER - TY - JOUR AU - Nair, S. AU - Dhodapkar, M. V. PY - 2017 DA - 2017// TI - Natural killer T cells in cancer immunotherapy JO - Front Immunol VL - 8 UR - https://doi.org/10.3389/fimmu.2017.01178 DO - 10.3389/fimmu.2017.01178 ID - Nair2017 ER - TY - JOUR AU - Tagliamonte, M. AU - Petrizzo, A. AU - Tornesello, M. L. AU - Buonaguro, F. M. AU - Buonaguro, L. PY - 2014 DA - 2014// TI - Antigen-specific vaccines for cancer treatment JO - Hum Vaccines Immunother VL - 10 UR - https://doi.org/10.4161/21645515.2014.973317 DO - 10.4161/21645515.2014.973317 ID - Tagliamonte2014 ER - TY - JOUR AU - Banchereau, J. AU - Steinman, R. M. PY - 1998 DA - 1998// TI - Dendritic cells and the control of immunity JO - Nature VL - 392 UR - https://doi.org/10.1038/32588 DO - 10.1038/32588 ID - Banchereau1998 ER - TY - JOUR AU - Tarte, K. AU - Fiol, G. AU - Rossi, J. F. AU - Klein, B. PY - 2000 DA - 2000// TI - Extensive characterization of dendritic cells generated in serum-free conditions: regulation of soluble antigen uptake, apoptotic tumor cell phagocytosis, chemotaxis and T cell activation during maturation in vitro JO - Leukemia VL - 14 UR - https://doi.org/10.1038/sj.leu.2401925 DO - 10.1038/sj.leu.2401925 ID - Tarte2000 ER - TY - JOUR AU - Kantoff, P. W. AU - Higano, C. S. AU - Shore, N. D. AU - Berger, E. R. AU - Small, E. J. AU - Penson, D. F. PY - 2010 DA - 2010// TI - Sipuleucel-T immunotherapy for castration-resistant prostate cancer JO - N Engl J Med VL - 363 UR - https://doi.org/10.1056/NEJMoa1001294 DO - 10.1056/NEJMoa1001294 ID - Kantoff2010 ER - TY - JOUR AU - Maloney, D. G. PY - 2007 DA - 2007// TI - Follicular NHL: from antibodies and vaccines to graft-versus-lymphoma effects JO - Hematol Am Soc Hematol Educ Progr UR - https://doi.org/10.1182/asheducation-2007.1.226 DO - 10.1182/asheducation-2007.1.226 ID - Maloney2007 ER - TY - JOUR AU - Bendandi, M. PY - 2000 DA - 2000// TI - Anti-idiotype vaccines for human follicular lymphoma JO - Leukemia VL - 14 UR - https://doi.org/10.1038/sj.leu.2401861 DO - 10.1038/sj.leu.2401861 ID - Bendandi2000 ER - TY - JOUR AU - Thomas, S. K. AU - Kwak, L. W. PY - 2012 DA - 2012// TI - Lymphoma vaccine therapy: next steps after a positive, controlled phase III clinical trial JO - Semin Oncol VL - 39 UR - https://doi.org/10.1053/j.seminoncol.2012.02.014 DO - 10.1053/j.seminoncol.2012.02.014 ID - Thomas2012 ER - TY - JOUR AU - Baudard, M. AU - Comte, F. AU - Conge, A. M. AU - Mariano-Goulart, D. AU - Klein, B. AU - Rossi, J. F. PY - 2007 DA - 2007// TI - Importance of [18F]fluorodeoxyglucose-positron emission tomography scanning for the monitoring of responses to immunotherapy in follicular lymphoma JO - Leuk Lymphoma VL - 48 UR - https://doi.org/10.1080/10428190601094354 DO - 10.1080/10428190601094354 ID - Baudard2007 ER - TY - JOUR AU - Anguille, S. AU - Smits, E. L. AU - Lion, E. AU - Tendeloo, V. F. AU - Berneman, Z. N. PY - 2014 DA - 2014// TI - Clinical use of dendritic cells for cancer therapy JO - Lancet Oncol VL - 15 UR - https://doi.org/10.1016/s1470-2045(13)70585-0 DO - 10.1016/s1470-2045(13)70585-0 ID - Anguille2014 ER - TY - JOUR AU - Schon, M. P. AU - Schon, M. PY - 2008 DA - 2008// TI - TLR7 and TLR8 as targets in cancer therapy JO - Oncogene VL - 27 UR - https://doi.org/10.1038/sj.onc.1210913 DO - 10.1038/sj.onc.1210913 ID - Schon2008 ER - TY - JOUR AU - Wimmers, F. AU - Schreibelt, G. AU - Skold, A. E. AU - Figdor, C. G. AU - Vries, I. J. PY - 2014 DA - 2014// TI - Paradigm shift in dendritic cell-based immunotherapy: from in vitro generated monocyte-derived DCs to naturally circulating DC subsets JO - Front Immunol VL - 5 UR - https://doi.org/10.3389/fimmu.2014.00165 DO - 10.3389/fimmu.2014.00165 ID - Wimmers2014 ER - TY - JOUR AU - Dubensky, T. W. AU - Reed, S. G. PY - 2010 DA - 2010// TI - Adjuvants for cancer vaccines JO - Semin Immunol VL - 22 UR - https://doi.org/10.1016/j.smim.2010.04.007 DO - 10.1016/j.smim.2010.04.007 ID - Dubensky2010 ER - TY - JOUR AU - Pizzurro, G. A. AU - Barrio, M. M. PY - 2015 DA - 2015// TI - Dendritic cell-based vaccine efficacy: aiming for hot spots JO - Front Immunol VL - 6 UR - https://doi.org/10.3389/fimmu.2015.00091 DO - 10.3389/fimmu.2015.00091 ID - Pizzurro2015 ER - TY - JOUR AU - Romagnoli, G. G. AU - Zelante, B. B. AU - Toniolo, P. A. AU - Migliori, I. K. AU - Barbuto, J. A. PY - 2014 DA - 2014// TI - Dendritic cell-derived exosomes may be a tool for cancer immunotherapy by converting tumor cells into immunogenic targets JO - Front Immunol VL - 5 UR - https://doi.org/10.3389/fimmu.2014.00692 DO - 10.3389/fimmu.2014.00692 ID - Romagnoli2014 ER - TY - JOUR AU - Ciocca, D. R. AU - Frayssinet, P. AU - Cuello-Carrion, F. D. PY - 2007 DA - 2007// TI - A pilot study with a therapeutic vaccine based on hydroxyapatite ceramic particles and self-antigens in cancer patients JO - Cell Stress Chaperones VL - 12 UR - https://doi.org/10.1379/CSC-218R.1 DO - 10.1379/CSC-218R.1 ID - Ciocca2007 ER - TY - JOUR AU - Marconato, L. AU - Frayssinet, P. AU - Rouquet, N. AU - Comazzi, S. AU - Leone, V. F. AU - Laganga, P. PY - 2014 DA - 2014// TI - Randomized, placebo-controlled, double-blinded chemoimmunotherapy clinical trial in a pet dog model of diffuse large B-cell lymphoma JO - Clin Cancer Res VL - 20 UR - https://doi.org/10.1158/1078-0432.ccr-13-2283 DO - 10.1158/1078-0432.ccr-13-2283 ID - Marconato2014 ER - TY - JOUR AU - Sanchez-Sanchez, N. AU - Riol-Blanco, L. AU - Rodriguez-Fernandez, J. L. PY - 2006 DA - 2006// TI - The multiple personalities of the chemokine receptor CCR1 in dendritic cells JO - J Immunol VL - 176 UR - https://doi.org/10.4049/jimmunol.176.9.5153 DO - 10.4049/jimmunol.176.9.5153 ID - Sanchez-Sanchez2006 ER - TY - JOUR AU - Tanyi, J. L. AU - Bobisse, S. AU - Ophir, E. AU - Tuyaerts, S. AU - Roberti, A. AU - Genolet, R. PY - 2018 DA - 2018// TI - Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer JO - Sci Transl Med UR - https://doi.org/10.1126/scitranslmed.aao5931 DO - 10.1126/scitranslmed.aao5931 ID - Tanyi2018 ER - TY - JOUR AU - Charni, S. AU - Bettignies, G. AU - Rathore, M. G. AU - Aguilo, J. I. AU - Elsen, P. J. AU - Haouzi, D. PY - 2010 DA - 2010// TI - Oxidative phosphorylation induces de novo expression of the MHC class I in tumor cells through the ERK5 pathway JO - J Immunol VL - 185 UR - https://doi.org/10.4049/jimmunol.1001250 DO - 10.4049/jimmunol.1001250 ID - Charni2010 ER - TY - JOUR AU - Pampena, M. B. AU - Levy, E. M. PY - 2015 DA - 2015// TI - Natural killer cells as helper cells in dendritic cell cancer vaccines JO - Front Immunol VL - 6 UR - https://doi.org/10.3389/fimmu.2015.00013 DO - 10.3389/fimmu.2015.00013 ID - Pampena2015 ER - TY - JOUR AU - Cartron, G. AU - Zhao-Yang, L. AU - Baudard, M. AU - Kanouni, T. AU - Rouille, V. AU - Quittet, P. PY - 2008 DA - 2008// TI - Granulocyte-macrophage colony-stimulating factor potentiates rituximab in patients with relapsed follicular lymphoma: results of a phase II study JO - J Clin Oncol VL - 26 UR - https://doi.org/10.1200/jco.2007.13.7729 DO - 10.1200/jco.2007.13.7729 ID - Cartron2008 ER - TY - JOUR AU - Chen, L. AU - Flies, D. B. PY - 2013 DA - 2013// TI - Molecular mechanisms of T cell co-stimulation and co-inhibition JO - Nat Rev Immunol VL - 13 UR - https://doi.org/10.1038/nri3405 DO - 10.1038/nri3405 ID - Chen2013 ER - TY - JOUR AU - Lines, J. L. AU - Sempere, L. F. AU - Broughton, T. AU - Wang, L. AU - Noelle, R. PY - 2014 DA - 2014// TI - VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy JO - Cancer Immunol Res VL - 2 UR - https://doi.org/10.1158/2326-6066.cir-14-0072 DO - 10.1158/2326-6066.cir-14-0072 ID - Lines2014 ER - TY - JOUR AU - Witzens-Harig, M. AU - Hose, D. AU - Junger, S. AU - Pfirschke, C. AU - Khandelwal, N. AU - Umansky, L. PY - 2013 DA - 2013// TI - Tumor cells in multiple myeloma patients inhibit myeloma-reactive T cells through carcinoembryonic antigen-related cell adhesion molecule-6 JO - Blood VL - 121 UR - https://doi.org/10.1182/blood-2012-05-429415 DO - 10.1182/blood-2012-05-429415 ID - Witzens-Harig2013 ER - TY - JOUR AU - Hodi, F. S. AU - O’Day, S. J. AU - McDermott, D. F. AU - Weber, R. W. AU - Sosman, J. A. AU - Haanen, J. B. PY - 2010 DA - 2010// TI - Improved survival with ipilimumab in patients with metastatic melanoma JO - N Engl J Med VL - 363 UR - https://doi.org/10.1056/NEJMoa1003466 DO - 10.1056/NEJMoa1003466 ID - Hodi2010 ER - TY - JOUR AU - Alsaab, H. O. AU - Sau, S. AU - Alzhrani, R. AU - Tatiparti, K. AU - Bhise, K. AU - Kashaw, S. K. PY - 2017 DA - 2017// TI - PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome JO - Front Pharmacol VL - 8 UR - https://doi.org/10.3389/fphar.2017.00561 DO - 10.3389/fphar.2017.00561 ID - Alsaab2017 ER - TY - STD TI - U.S. National Library of Medicine. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/results?term=immune+checkpoint+inhibitors+clinical+trials&Search=Search. Accessed 16 May 2019. UR - https://clinicaltrials.gov/ct2/results%3fterm%3dimmune%2bcheckpoint%2binhibitors%2bclinical%2btrials%26Search%3dSearch ID - ref125 ER - TY - JOUR AU - Jackson, S. R. AU - Yuan, J. AU - Teague, R. M. PY - 2014 DA - 2014// TI - Targeting CD8+ T-cell tolerance for cancer immunotherapy JO - Immunotherapy VL - 6 UR - https://doi.org/10.2217/imt.14.51 DO - 10.2217/imt.14.51 ID - Jackson2014 ER - TY - JOUR AU - Bracci, L. AU - Schiavoni, G. AU - Sistigu, A. AU - Belardelli, F. PY - 2014 DA - 2014// TI - Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer JO - Cell Death Differ VL - 21 UR - https://doi.org/10.1038/cdd.2013.67 DO - 10.1038/cdd.2013.67 ID - Bracci2014 ER - TY - JOUR AU - Ali, K. AU - Soond, D. R. AU - Pineiro, R. AU - Hagemann, T. AU - Pearce, W. AU - Lim, E. L. PY - 2014 DA - 2014// TI - Inactivation of PI(3)K p110delta breaks regulatory T-cell-mediated immune tolerance to cancer JO - Nature VL - 510 UR - https://doi.org/10.1038/nature13444 DO - 10.1038/nature13444 ID - Ali2014 ER - TY - JOUR AU - Medina-Echeverz, J. AU - Aranda, F. AU - Berraondo, P. PY - 2014 DA - 2014// TI - Myeloid-derived cells are key targets of tumor immunotherapy JO - Oncoimmunology VL - 3 UR - https://doi.org/10.4161/onci.28398 DO - 10.4161/onci.28398 ID - Medina-Echeverz2014 ER - TY - JOUR AU - Natarajan, G. AU - Oghumu, S. AU - Terrazas, C. AU - Varikuti, S. AU - Byrd, J. C. AU - Satoskar, A. R. PY - 2016 DA - 2016// TI - A Tec kinase BTK inhibitor ibrutinib promotes maturation and activation of dendritic cells JO - Oncoimmunology VL - 5 UR - https://doi.org/10.1080/2162402x.2016.1151592 DO - 10.1080/2162402x.2016.1151592 ID - Natarajan2016 ER - TY - JOUR AU - Liu, X. AU - Shin, N. AU - Koblish, H. K. AU - Yang, G. AU - Wang, Q. AU - Wang, K. PY - 2010 DA - 2010// TI - Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity JO - Blood VL - 115 UR - https://doi.org/10.1182/blood-2009-09-246124 DO - 10.1182/blood-2009-09-246124 ID - Liu2010 ER - TY - JOUR AU - Condomines, M. AU - Veyrune, J. L. AU - Larroque, M. AU - Quittet, P. AU - Latry, P. AU - Lugagne, C. PY - 2010 DA - 2010// TI - Increased plasma-immune cytokines throughout the high-dose melphalan- induced lymphodepletion in patients with multiple myeloma: a window for adoptive immunotherapy JO - J Immunol VL - 184 UR - https://doi.org/10.4049/jimmunol.0804159 DO - 10.4049/jimmunol.0804159 ID - Condomines2010 ER - TY - JOUR AU - Rossi, J. F. AU - Fegueux, N. AU - Lu, Z. Y. AU - Legouffe, E. AU - Exbrayat, C. AU - Bozonnat, M. C. PY - 2005 DA - 2005// TI - Optimizing the use of anti-interleukin-6 monoclonal antibody with dexamethasone and 140 mg/m2 of melphalan in multiple myeloma: results of a pilot study including biological aspects JO - Bone Marrow Transplant VL - 36 UR - https://doi.org/10.1038/sj.bmt.1705138 DO - 10.1038/sj.bmt.1705138 ID - Rossi2005 ER - TY - JOUR AU - Perales, M. A. AU - Sauter, C. S. AU - Armand, P. PY - 2016 DA - 2016// TI - Fast cars and no brakes: autologous stem cell transplantation as a platform for novel immunotherapies JO - Biol Blood Marrow Transplant VL - 22 UR - https://doi.org/10.1016/j.bbmt.2015.10.014 DO - 10.1016/j.bbmt.2015.10.014 ID - Perales2016 ER -